Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcus Biosciences, Inc.RCUS · Entity 4104 | Chief Operating Officer | January 23, 2026 | January 27, 2026 |
| Damora Therapeutics, Inc.DMRA · Entity 4602 | Director · Director, President and CEO | September 25, 2026 | September 28, 2026 |
| Sagimet Biosciences Inc.SGMT · Entity 5273 | Director | June 12, 2026 | June 15, 2026 |
| Syndax Pharmaceuticals IncSNDX · Entity 4578 | Director | February 04, 2026 | February 06, 2026 |
| Zura Bio LtdZURA · Entity 5413 | Director | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcus Biosciences, Inc.
Report date January 23, 2026 · Filed January 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 224,024 |
Reported balance
After 2026-01-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-23 · Grant · Acquired 31,000 · Balance 224,024 F1: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. F2: Includes the unvested portion of the Reporting Person's RSU grants. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.13 · Expires 2036-01-22 | Direct | 126,000 |
Reported balance
After 2026-01-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-23 · Grant · Acquired 126,000 · Balance 126,000 F3: The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company.
F2: Includes the unvested portion of the Reporting Person's RSU grants.
F3: The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.
Damora Therapeutics, Inc.
Report date September 25, 2026 · Filed September 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 512,500 |
Reported balance
After 2026-09-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-25 · Purchase · Acquired 12,500 · Balance 512,500 F1: Represents shares purchased on the open market at prevailing market prices using personal funds. F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.10 to $20.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3: Includes 500,000 restricted stock units ("RSUs") previously granted to the Reporting Person. Each RSU represents the right to receive, at settlement, one ordinary share of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares purchased on the open market at prevailing market prices using personal funds.
F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.10 to $20.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3: Includes 500,000 restricted stock units ("RSUs") previously granted to the Reporting Person. Each RSU represents the right to receive, at settlement, one ordinary share of the Issuer.
Sagimet Biosciences Inc.
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.48 · Expires 2036-06-11 | Direct | 39,567 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 39,567 · Balance 39,567 F1: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date.
Syndax Pharmaceuticals Inc
Report date February 04, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 114,000 |
Reported balance
After 2026-02-04 transaction · row 1
1 source rowRow 1 · 2026-02-04 · Grant · Acquired 24,000 · Balance 114,000 F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.
Zura Bio Ltd
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.62 · Expires 2036-06-17 | Direct | 51,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 51,000 · Balance 51,000 F1: This option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date.
Past disclosures · reporting ended (5)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARENA PHARMACEUTICALS INC
Report date March 11, 2022 · Filed March 11, 2022
Section 16 reporting ended · disclosed 2022-03-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-03-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-03-11 · Other · Disposed 8,150 · Balance 3,067 F1: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes. Row 2 · 2022-03-11 · Other · Disposed 3,067 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.60 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-11 · Disposition to issuer · Disposed 7,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.60 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-03-11 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.17 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-03-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.50 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-03-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.31 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-03-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.19 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-03-11 · Disposition to issuer · Disposed 7,202 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes.
F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes.
F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes.
Audentes Therapeutics, Inc.
Report date January 15, 2020 · Filed January 15, 2020
Section 16 reporting ended · disclosed 2020-01-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.70 · Expires 2027-06-12 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-15 · Disposition to issuer · Disposed 18,000 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.15 · Expires 2027-10-08 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-01-15 · Disposition to issuer · Disposed 9,000 · Balance 0 F3: Reflects the correct exercise price of this option. The exercise price of this option was previously reported as $26.01. F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.65 · Expires 2028-06-08 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-01-15 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.74 · Expires 2029-02-06 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-01-15 · Disposition to issuer · Disposed 16,200 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price.
F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
F3: Reflects the correct exercise price of this option. The exercise price of this option was previously reported as $26.01.
MEDIVATION, INC.
Report date September 28, 2016 · Filed September 30, 2016
Section 16 reporting ended · disclosed 2016-09-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 1
1 source rowRow 1 · 2016-09-28 · Disposition to issuer · Disposed 29,971 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. F2: Represents unvested restricted stock units (the "RSUs") that were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such RSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.45 · Expires 2026-04-08 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-09-28 · Disposition to issuer · Disposed 119,885 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Performance-Based Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2020-04-07 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-09-28 · Disposition to issuer · Disposed 37,463 · Balance 0 F4: The number of shares subject to the performance-based restricted stock unit (the "PSUs") is based on deemed satisfaction of all applicable performance goals at the maximum levels. F5: The PSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such PSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the PSUs was accelerated and the PSUs became fully vested effective immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal.
F2: Represents unvested restricted stock units (the "RSUs") that were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such RSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger.
F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
F4: The number of shares subject to the performance-based restricted stock unit (the "PSUs") is based on deemed satisfaction of all applicable performance goals at the maximum levels.
F5: The PSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such PSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the PSUs was accelerated and the PSUs became fully vested effective immediately prior to the effective time of the Merger.
Radius Health, Inc.
Report date August 15, 2022 · Filed August 15, 2022
Section 16 reporting ended · disclosed 2022-08-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.84 · Expires 2032-05-18 | Direct | 0 |
Reported balance
After 2022-08-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-15 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time, these options automatically vested and were cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (without interest) (A) an amount in cash (less applicable Tax withholdings) equal to the product of (x) the total number of Shares subject to such option immediately prior to the effective time multiplied by (y) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option, and (B) one CVR for each Share subject thereto. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Merger Agreement, at the Effective Time, these options automatically vested and were cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (without interest) (A) an amount in cash (less applicable Tax withholdings) equal to the product of (x) the total number of Shares subject to such option immediately prior to the effective time multiplied by (y) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option, and (B) one CVR for each Share subject thereto.
Surrozen, Inc./DE
Report date August 11, 2021 · Filed August 13, 2021
Section 16 reporting ended · disclosed 2021-08-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
After 2021-08-11 transaction · row 1
1 source rowRow 1 · 2021-08-11 · Grant · Acquired 30,000 · Balance 30,000 F1: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.", F2: (Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination". |
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-08-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-08-11 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.", F2: (Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination". |
Filing footnotes · ownership attribution and instrument terms
F1: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.",
F2: (Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination".
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 25, 2026 Filed Sep 28, 2026 11:00 UTC | Damora Therapeutics, Inc. DMRA · Entity 4602 | PurchaseOrdinary Shares | 12,500 | $20.23 | $252,875.00 |
DisclosureSEC source: 0001193125-26-403355 · ownership.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director · Director, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 512,500 F1 · kind: Represents shares purchased on the open market at prevailing market prices using personal funds. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.10 to $20.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 500,000 restricted stock units ("RSUs") previously granted to the Reporting Person. Each RSU represents the right to receive, at settlement, one ordinary share of the Issuer. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:15 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantShare Option (Right to Buy) · Derivative | 51,000 | $0.00 Strike: $3.62 | $0.00 |
DisclosureSEC source: 0001671311-26-000005 · form4-06222026_040612.xml · derivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,000 Underlying: Class A Ordinary Shares · 51,000 shares Expires 2036-06-17 F1 · derivative.exercise_date: This option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| June 12, 2026 Filed Jun 15, 2026 20:21 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 39,567 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0001104659-26-074050 · tm2617570-4_4seq1.xml · derivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,567 Underlying: Series A Common Stock · 39,567 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 21:30 UTC | Damora Therapeutics, Inc. DMRA · Entity 4602 | GrantStock Option (right to buy) · Derivative | 1,500,000 | $0.00 Strike: $25.50 | $0.00 |
DisclosureSEC source: 0001193125-26-138275 · ownership.xml · derivative · entry 2 Jarrett Jennifer · CIK 0001671311 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Common Stock · 1,500,000 shares Expires 2036-03-30 F2 · derivative.exercise_date: This option represents a right to purchase shares of common stock of the Issuer. This option will vest as to 25% on March 30, 2027 and in equal monthly installments thereafter through March 30, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 21:30 UTC | Damora Therapeutics, Inc. DMRA · Entity 4602 | GrantCommon Stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-138275 · ownership.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 F1 · security: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents the right to receive, at settlement, one share of common stock of the Issuer. The RSUs will vest with respect to 25% on each anniversary of the grant date through the fourth anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 22:16 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-041412 · ownership.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 01:21 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 126,000 | $0.00 Strike: $22.13 | $0.00 |
DisclosureSEC source: 0001671311-26-000002 · wk-form4_1769476873.xml · derivative · entry 2 Jarrett Jennifer · CIK 0001671311 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,000 Underlying: Common Stock · 126,000 shares Expires 2036-01-22 F3 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 01:21 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001671311-26-000002 · wk-form4_1769476873.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,024 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. F2 · balance_after: Includes the unvested portion of the Reporting Person's RSU grants. Read SEC document |
| December 17, 2025 Filed Dec 18, 2025 22:35 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 9,983 | $22.16 | $221,218.29 |
DisclosureSEC source: 0001671311-25-000009 · wk-form4_1766097311.xml · nonDerivative · entry 2 Jarrett Jennifer · CIK 0001671311 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 193,024 F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes the unvested portion of the reporting person's RSU grants. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 22:35 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 11,225 | $21.88 | $245,651.27 |
DisclosureSEC source: 0001671311-25-000009 · wk-form4_1766097311.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 203,007 F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.42 to $22.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes the unvested portion of the reporting person's RSU grants. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:04 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,291 | $1.23 Strike: $1.23 | $61,737.23 |
DisclosureSEC source: 0001671311-25-000005 · wk-form4_1762981456.xml · derivative · entry 3 Jarrett Jennifer · CIK 0001671311 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,583 Underlying: Common Stock · 50,291 shares Expires 2027-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: The option is fully vested and currently exercisable. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:04 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 50,291 | $18.97 | $954,065.53 |
DisclosureSEC source: 0001671311-25-000005 · wk-form4_1762981456.xml · nonDerivative · entry 2 Jarrett Jennifer · CIK 0001671311 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 214,232 F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.59 to $19.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:04 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Exercise / conversionCommon Stock | 50,291 | $1.23 | $61,737.23 |
DisclosureSEC source: 0001671311-25-000005 · wk-form4_1762981456.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 264,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 08, 2025 Filed Oct 8, 2025 23:08 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Exercise / conversionStock Option (Right to Buy) · Derivative | 37,792 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001671311-25-000003 · wk-form4_1759964895.xml · derivative · entry 6 Jarrett Jennifer · CIK 0001671311 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,874 Underlying: Common Stock · 37,792 shares Expires 2027-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: The option is fully vested and currently exercisable. Read SEC document |
| October 08, 2025 Filed Oct 8, 2025 23:08 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 37,792 | $15.05 | $568,610.87 |
DisclosureSEC source: 0001671311-25-000003 · wk-form4_1759964895.xml · nonDerivative · entry 4 Jarrett Jennifer · CIK 0001671311 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 214,232 F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: Includes 863 shares purchased on 5/30/2025 through the Company's Employee Stock Purchase Plan. Read SEC document |
| October 08, 2025 Filed Oct 8, 2025 23:08 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Exercise / conversionCommon Stock | 37,792 | $1.23 | $46,393.46 |
DisclosureSEC source: 0001671311-25-000003 · wk-form4_1759964895.xml · nonDerivative · entry 3 Jarrett Jennifer · CIK 0001671311 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 252,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 863 shares purchased on 5/30/2025 through the Company's Employee Stock Purchase Plan. Read SEC document |
| October 06, 2025 Filed Oct 8, 2025 23:08 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001671311-25-000003 · wk-form4_1759964895.xml · derivative · entry 5 Jarrett Jennifer · CIK 0001671311 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,666 Underlying: Common Stock · 12,500 shares Expires 2027-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: The option is fully vested and currently exercisable. Read SEC document |
| October 06, 2025 Filed Oct 8, 2025 23:08 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 12,500 | $14.54 | $181,801.25 |
DisclosureSEC source: 0001671311-25-000003 · wk-form4_1759964895.xml · nonDerivative · entry 2 Jarrett Jennifer · CIK 0001671311 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 214,232 F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.40 to $14.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: Includes 863 shares purchased on 5/30/2025 through the Company's Employee Stock Purchase Plan. Read SEC document |
| October 06, 2025 Filed Oct 8, 2025 23:08 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Exercise / conversionCommon Stock | 12,500 | $1.23 | $15,345.00 |
DisclosureSEC source: 0001671311-25-000003 · wk-form4_1759964895.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 226,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 863 shares purchased on 5/30/2025 through the Company's Employee Stock Purchase Plan. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 21:38 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 27,268 | $0.00 Strike: $5.33 | $0.00 |
DisclosureSEC source: 0001104659-25-058222 · tm2517621-3_4seq1.xml · derivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,268 Underlying: Series A Common Stock · 27,268 shares Expires 2035-06-08 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| May 21, 2025 Filed May 22, 2025 21:33 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantShare Option (Right to Buy) · Derivative | 51,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001415889-25-014215 · form4-05222025_090513.xml · derivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,000 Underlying: Class A Ordinary Shares · 51,000 shares Expires 2035-05-21 F1 · derivative.exercise_date: This option vests in twelve substantially equal monthly installments over a one-year period measured from May 21, 2025; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:35 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-016357 · ownership.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:30 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $13.33 | $0.00 |
DisclosureSEC source: 0001724521-25-000018 · wk-form4_1738013425.xml · derivative · entry 2 Jarrett Jennifer · CIK 0001671311 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2035-01-22 F2 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2025, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:30 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001724521-25-000018 · wk-form4_1738013425.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,369 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2025, subject to the Reporting Person's continued service to the Company. Read SEC document |
| December 15, 2024 Filed Dec 18, 2024 01:37 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Tax withholdingCommon Stock | 27,501 | $16.08 | $442,216.08 |
DisclosureSEC source: 0001724521-24-000184 · wk-form4_1734485815.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,369 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy the applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| December 09, 2024 Filed Dec 11, 2024 21:48 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantShare Option (Right to Buy) · Derivative | 117,000 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001415889-24-028983 · form4-12112024_091204.xml · derivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,000 Underlying: Class A Ordinary Shares · 117,000 shares Expires 2034-12-09 F1 · derivative.exercise_date: This option vests in twelve substantially equal monthly installments over a one-year period measured from October 23, 2024; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| September 15, 2024 Filed Sep 17, 2024 22:42 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Tax withholdingCommon Stock | 12,670 | $17.95 | $227,426.50 |
DisclosureSEC source: 0001724521-24-000150 · wk-form4_1726612931.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,394 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy the applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:09 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 113,895 | $0.00 Strike: $3.48 | $0.00 |
DisclosureSEC source: 0001104659-24-085820 · tm2420761-4_4seq1.xml · derivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,895 Underlying: Series A Common Stock · 113,895 shares Expires 2034-07-31 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable over thirty-six (36) equal monthly installments following August 1, 2024, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 15, 2024 Filed Jun 18, 2024 20:54 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Tax withholdingCommon Stock | 12,670 | $16.97 | $215,009.90 |
DisclosureSEC source: 0001724521-24-000127 · wk-form4_1718744038.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,064 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy the applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. F2 · balance_after: Includes 481 shares purchased on 5/31/2024 through the Company's Employee Stock Purchase Plan. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 20:20 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 11,551 | $17.55 | $202,720.05 |
DisclosureSEC source: 0001724521-24-000071 · wk-form4_1711743618.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 215,253 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 22, 2023. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.53 to $17.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 20:19 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 1,296 | $18.62 | $24,131.52 |
DisclosureSEC source: 0001724521-24-000068 · wk-form4_1710965959.xml · nonDerivative · entry 2 Jarrett Jennifer · CIK 0001671311 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 226,804 F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.44 to $18.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 20:19 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 12,153 | $17.84 | $216,809.52 |
DisclosureSEC source: 0001724521-24-000068 · wk-form4_1710965959.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 228,100 F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.39 to $18.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 00:55 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 34,070 | $20.11 | $685,147.70 |
DisclosureSEC source: 0001724521-24-000063 · wk-form4_1709168145.xml · nonDerivative · entry 2 Jarrett Jennifer · CIK 0001671311 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 240,253 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 22, 2023. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 00:55 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 24,555 | $20.07 | $492,818.85 |
DisclosureSEC source: 0001724521-24-000063 · wk-form4_1709168145.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 274,323 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 22, 2023. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 21:04 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001219 · primarydocument.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 00:39 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 162,400 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001724521-24-000025 · wk-form4_1706229543.xml · derivative · entry 2 Jarrett Jennifer · CIK 0001671311 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,400 Underlying: Common Stock · 162,400 shares Expires 2034-01-22 F2 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2024, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 00:39 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001724521-24-000025 · wk-form4_1706229543.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 298,878 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2024, subject to the Reporting Person's continued service to the Company. Read SEC document |
| December 22, 2023 Filed Dec 26, 2023 21:04 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 21,521 | $17.76 | $382,212.96 |
DisclosureSEC source: 0001724521-23-000076 · wk-form4_1703624687.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 258,878 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 22, 2023. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.50 to $18.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 19, 2023 Filed Dec 20, 2023 21:09 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Disposition to issuerCommon Stock | 11,492 | $18.09 | $207,890.28 |
DisclosureSEC source: 0001724521-23-000066 · wk-form4_1703106578.xml · nonDerivative · entry 2 Jarrett Jennifer · CIK 0001671311 · Director · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 280,399 F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.78 to $18.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 21:09 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Disposition to issuerCommon Stock | 11,250 | $17.74 | $199,575.00 |
DisclosureSEC source: 0001724521-23-000066 · wk-form4_1703106578.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 291,891 F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.45 to $17.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 450 shares purchased on 11/30/2023 through the Company's Employee Stock Purchase Plan. Read SEC document |
| September 22, 2023 Filed Sep 26, 2023 20:35 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 21,369 | $19.99 | $427,166.31 |
DisclosureSEC source: 0001724521-23-000011 · wk-form4_1695760547.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 302,691 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 22, 2023. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.74 to $20.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 20:46 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Disposition to issuerCommon Stock | 12,506 | $20.40 | $255,122.40 |
DisclosureSEC source: 0001724521-23-000006 · wk-form4_1695242751.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 324,060 F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person. Read SEC document |
| July 28, 2023 Filed Jul 31, 2023 20:15 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 45,000 | $20.25 | $911,250.00 |
DisclosureSEC source: 0001209191-23-043821 · doc4.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 336,566 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 22, 2023. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 20:36 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 12,437 | $19.12 | $237,795.44 |
DisclosureSEC source: 0001209191-23-039718 · doc4.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 381,566 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 22, 2023. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.78 to $19.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 16, 2023 Filed Jun 17, 2023 00:16 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 12,563 | $19.35 | $243,094.05 |
DisclosureSEC source: 0001209191-23-038157 · doc4.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 394,003 F1 · shares: Represents shares sold by the Issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.86 to $19.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 349 shares purchased on 5/31/2023 through the Company's Employee Stock Purchase Plan. Read SEC document |
| May 18, 2023 Filed May 23, 2023 01:17 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantEmployee Share Option (Right to Buy) · Derivative | 7,652 | $0.00 Strike: $5.31 | $0.00 |
DisclosureSEC source: 0001104659-23-063317 · tm2316481-6_4seq1.xml · derivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,652 Underlying: Class A Ordinary Shares · 7,652 shares Expires 2033-05-18 F1 · derivative.exercise_date: The option shall vest and become fully exercisable on the earlier of (i) May 18, 2024 or (ii) the date of the next annual meeting of shareholders of Zura Bio Limited. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 20:12 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 8,729 | $16.81 | $146,734.49 |
DisclosureSEC source: 0001209191-23-020037 · doc4.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 406,217 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.66 to $16.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 21:52 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-000942 · primarydocument.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
| January 27, 2023 Filed Jan 30, 2023 22:04 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 1,600 | $23.52 | $37,632.00 |
DisclosureSEC source: 0001209191-23-005513 · doc4.xml · nonDerivative · entry 2 Jarrett Jennifer · CIK 0001671311 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 414,946 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.50 to $23.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 22:04 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 300 | $23.56 | $7,068.00 |
DisclosureSEC source: 0001209191-23-005513 · doc4.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,546 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.50 to $23.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.